Bausch Health Companies Inc. Business Acquisition, Pro Forma Revenue
Bausch Health Companies Inc. (BHC) reported Business Acquisition, Pro Forma Revenue of $10.71 billion for the 12-month period ending 2015-12-31, per its 8-K filed 2018-08-10.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2018-08-10
- Bausch Health Companies Inc. business acquisition, pro forma revenue for the quarter ending 2015-12-31 was $2.77B, a 4.42% increase year-over-year.
- Bausch Health Companies Inc. business acquisition, pro forma revenue for the quarter ending 2015-09-30 was $2.86B, a 12.75% increase year-over-year.
- Bausch Health Companies Inc. business acquisition, pro forma revenue for the quarter ending 2015-06-30 was $2.81B, a 8.06% increase year-over-year.
- Bausch Health Companies Inc. business acquisition, pro forma revenue for the quarter ending 2015-03-31 was $2.27B, a 10.45% increase year-over-year.
- Bausch Health Companies Inc. business acquisition, pro forma revenue for fiscal 2014 was $10.25B, a 29.23% increase from fiscal 2013.
- Bausch Health Companies Inc. business acquisition, pro forma revenue for fiscal 2013 was $7.93B, a 2.98% increase from fiscal 2012.
- Bausch Health Companies Inc. business acquisition, pro forma revenue for fiscal 2012 was $7.70B, a 86.12% increase from fiscal 2011.
- Bausch Health Companies Inc. business acquisition, pro forma revenue for fiscal 2011 was $4.14B, a 57.66% increase from fiscal 2010.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 3 month as first filed | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 6 month as first filed | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 9 month as first filed | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | $2.77B derived: 8-K 12 month − 10-Q 9 month · filed 2018-08-10 | $5.63B derived: sum of 2 quarters · filed 2018-08-10 | $8.44B derived: sum of 3 quarters · filed 2018-08-10 | $10.71B 8-K · filed 2018-08-10 | $10.71B 10-K · filed 2016-04-29 | |||
| 2015-09-30 | $2.86B 10-Q · filed 2016-11-09 | $2.79B 10-Q · filed 2015-10-26 | $5.67B derived: sum of 2 quarters · filed 2016-11-09 | $7.94B 10-Q · filed 2016-11-09 | $7.74B 10-Q · filed 2015-10-26 | $10.59B derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2015-06-30 | $2.81B 10-Q · filed 2016-08-09 | $2.73B 10-Q · filed 2015-07-28 | $5.08B 10-Q · filed 2016-08-09 | $4.88B 10-Q · filed 2015-07-28 | $7.73B derived: sum of 3 quarters · filed 2017-03-01 | $10.27B derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2015-03-31 | $2.27B 10-Q · filed 2016-06-07 | $2.27B 10-Q · filed 2015-04-30 | $4.93B derived: sum of 2 quarters · filed 2017-03-01 | $7.46B derived: sum of 3 quarters · filed 2017-03-01 | $10.06B derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | $2.65B derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $5.19B derived: sum of 2 quarters · filed 2017-03-01 | $7.79B derived: sum of 3 quarters · filed 2017-03-01 | $10.25B 10-K · filed 2017-03-01 | $8.35B 10-K · filed 2015-02-25 | |||
| 2014-09-30 | $2.54B 10-Q · filed 2015-10-26 | $2.06B 10-Q · filed 2014-10-24 | $5.13B derived: sum of 2 quarters · filed 2015-10-26 | $7.59B 10-Q · filed 2015-10-26 | $6.04B 10-Q · filed 2014-10-24 | $9.33B derived: sum of 4 quarters · filed 2016-04-29 | ||
| 2014-06-30 | $2.60B 10-Q · filed 2015-07-28 | $2.04B 10-Q · filed 2014-08-01 | $5.06B 10-Q · filed 2015-07-28 | $3.93B 10-Q · filed 2014-08-01 | $6.79B derived: sum of 3 quarters · filed 2016-04-29 | $8.65B derived: sum of 4 quarters · filed 2016-04-29 | ||
| 2014-03-31 | $2.06B 10-Q · filed 2015-04-30 | $1.89B 10-Q · filed 2014-05-09 | $4.19B derived: sum of 2 quarters · filed 2016-04-29 | $6.06B derived: sum of 3 quarters · filed 2016-04-29 | $8.02B derived: sum of 4 quarters · filed 2016-04-29 | |||
| 2013-12-31 | $2.13B derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29 | $4.00B derived: sum of 2 quarters · filed 2016-04-29 | $5.96B derived: sum of 3 quarters · filed 2016-04-29 | $7.93B 10-K · filed 2016-04-29 | $7.67B 10-K · filed 2014-02-28 | |||
| 2013-09-30 | $1.87B 10-Q · filed 2014-10-24 | $1.81B 10-Q · filed 2013-11-01 | $3.82B derived: sum of 2 quarters · filed 2014-10-24 | $5.79B 10-Q · filed 2014-10-24 | $5.60B 10-Q · filed 2013-11-01 | $7.70B derived: sum of 4 quarters · filed 2015-02-25 | ||
| 2013-06-30 | $1.96B 10-Q · filed 2014-08-01 | $1.10B 10-Q · filed 2013-08-07 | $3.87B 10-Q · filed 2014-08-01 | $2.22B 10-Q · filed 2013-08-07 | $5.83B derived: sum of 3 quarters · filed 2015-02-25 | $7.74B derived: sum of 4 quarters · filed 2015-02-25 | ||
| 2013-03-31 | $1.92B 10-Q · filed 2014-05-09 | $1.08B 10-Q · filed 2013-05-03 | $3.87B derived: sum of 2 quarters · filed 2015-02-25 | $5.78B derived: sum of 3 quarters · filed 2015-02-25 | $6.92B derived: sum of 4 quarters · filed 2015-02-25 | |||
| 2012-12-31 | $1.96B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $3.87B derived: sum of 2 quarters · filed 2015-02-25 | $5.00B derived: sum of 3 quarters · filed 2015-02-25 | $7.70B 10-K · filed 2015-02-25 | $4.38B 10-K · filed 2013-02-28 | |||
| 2012-09-30 | $1.91B 10-Q · filed 2013-11-01 | $901.63M 10-Q · filed 2012-11-05 | $3.05B derived: sum of 2 quarters · filed 2013-11-01 | $5.75B 10-Q · filed 2013-11-01 | $2.69B 10-Q · filed 2012-11-05 | $5.92B derived: sum of 4 quarters · filed 2013-11-01 | ||
| 2012-06-30 | $1.14B 10-Q · filed 2013-08-07 | $848.29M 10-Q · filed 2012-08-03 | $2.34B 10-Q · filed 2013-08-07 | $1.75B 10-Q · filed 2012-08-03 | $4.01B derived: sum of 3 quarters · filed 2013-08-07 | $4.81B derived: sum of 4 quarters · filed 2013-08-07 | ||
| 2012-03-31 | $1.17B 10-Q · filed 2013-05-03 | $864.64M 10-Q · filed 2012-05-04 | $2.87B derived: sum of 2 quarters · filed 2013-05-03 | $3.68B derived: sum of 3 quarters · filed 2013-05-03 | $4.47B derived: sum of 4 quarters · filed 2013-05-03 | |||
| 2011-12-31 | $1.70B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $2.51B derived: sum of 2 quarters · filed 2013-02-28 | $3.30B derived: sum of 3 quarters · filed 2013-02-28 | $4.14B 10-K · filed 2013-02-28 | $2.93B 10-K · filed 2012-02-29 | |||
| 2011-09-30 | $805.66M 10-Q · filed 2012-11-05 | $615.51M 10-Q · filed 2011-11-04 | $1.59B derived: sum of 2 quarters · filed 2012-11-05 | $2.43B 10-Q · filed 2012-11-05 | $1.90B 10-Q · filed 2011-11-04 | $3.29B derived: sum of 4 quarters · filed 2012-11-05 | ||
| 2011-06-30 | $788.80M 10-Q · filed 2012-08-03 | $609.39M 10-Q · filed 2011-08-08 | $1.58B 10-Q · filed 2012-08-03 | $1.22B 10-Q · filed 2011-08-08 | $2.49B derived: sum of 3 quarters · filed 2012-08-03 | $3.05B derived: sum of 4 quarters · filed 2012-08-03 | ||
| 2011-03-31 | $752.12M 10-Q · filed 2012-05-04 | $1.70B derived: sum of 2 quarters · filed 2012-05-04 | $2.26B derived: sum of 3 quarters · filed 2012-05-04 | $2.80B derived: sum of 4 quarters · filed 2012-05-04 | ||||
| 2010-12-31 | $947.45M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $1.50B derived: sum of 2 quarters · filed 2012-02-29 | $2.05B derived: sum of 3 quarters · filed 2012-02-29 | $2.62B 10-K · filed 2012-02-29 | ||||
| 2010-09-30 | $557.33M 10-Q · filed 2011-11-04 | $1.10B derived: sum of 2 quarters · filed 2011-11-04 | $1.68B 10-Q · filed 2011-11-04 | |||||
| 2010-06-30 | $546.42M 10-Q · filed 2011-08-08 | $1.05B 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |